Year |
Citation |
Score |
2023 |
Koelsch N, Manjili MH. From Reductionistic Approach to Systems Immunology Approach for the Understanding of Tumor Microenvironment. International Journal of Molecular Sciences. 24. PMID 37569461 DOI: 10.3390/ijms241512086 |
0.471 |
|
2023 |
Qian J, Yu X, Liu Z, Cai J, Manjili MH, Yang H, Guo C, Wang XY. SRA inhibition improves antitumor potency of antigen-targeted chaperone vaccine. Frontiers in Immunology. 14: 1118781. PMID 36793731 DOI: 10.3389/fimmu.2023.1118781 |
0.354 |
|
2022 |
Manjili MH, Khazaie K. Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways. Seminars in Cancer Biology. 78: 1-4. PMID 34990835 DOI: 10.1016/j.semcancer.2021.12.008 |
0.398 |
|
2021 |
Manjili SH, Isbell M, Ghochaghi N, Perkinson T, Manjili MH. Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse. Seminars in Cancer Biology. PMID 33785450 DOI: 10.1016/j.semcancer.2021.03.023 |
0.359 |
|
2021 |
Liu Z, Guo C, Das SK, Yu X, Pradhan AK, Li X, Ning Y, Chen S, Liu W, Windle JJ, Bear HD, Manjili MH, Fisher PB, Wang XY. Engineering T cells to express tumoricidal MDA-7/IL-24 enhances cancer immunotherapy. Cancer Research. PMID 33727225 DOI: 10.1158/0008-5472.CAN-20-2604 |
0.455 |
|
2020 |
Aqbi HF, Coleman C, Zarei M, Manjili SH, Graham L, Koblinski J, Guo C, Xie Y, Guruli G, Bear HD, Idowu MO, Habibi M, Wang XY, Manjili MH. Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets. Breast Cancer Research : Bcr. 22: 116. PMID 33115528 DOI: 10.1186/s13058-020-01357-9 |
0.372 |
|
2020 |
Patel NH, Sohal SS, Manjili MH, Harrell JC, Gewirtz DA. The Roles of Autophagy and Senescence in the Tumor Cell Response to Radiation. Radiation Research. 194: 103-115. PMID 32845995 DOI: 10.1667/Rade-20-00009 |
0.452 |
|
2020 |
Manjili RH, Zarei M, Habibi M, Manjili MH. COVID-19 as an Acute Inflammatory Disease. Journal of Immunology (Baltimore, Md. : 1950). PMID 32423917 DOI: 10.4049/Jimmunol.2000413 |
0.303 |
|
2020 |
Manjili MH. The premise of personalized immunotherapy for cancer dormancy. Oncogene. PMID 32322001 DOI: 10.1038/S41388-020-1295-3 |
0.469 |
|
2019 |
Jahanban-Esfahlan R, Seidi K, Manjili MH, Jahanban-Esfahlan A, Javaheri T, Zare P. Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer. Cancers. 11. PMID 31430951 DOI: 10.3390/Cancers11081207 |
0.429 |
|
2018 |
Salman A, Koparde V, Hall CE, Jameson-Lee M, Roberts C, Serrano M, AbdulRazzaq B, Meier J, Kennedy C, Manjili MH, Spellman SR, Wijesinghe D, Hashmi S, Buck G, Qayyum R, et al. Determining the Quantitative Principles of T Cell Response to Antigenic Disparity in Stem Cell Transplantation. Frontiers in Immunology. 9: 2284. PMID 30364159 DOI: 10.3389/Fimmu.2018.02284 |
0.371 |
|
2018 |
Payne KK, Aqbi HF, Butler SE, Graham L, Keim RC, Wan W, Idowu MO, Bear HD, Wang XY, Manjili MH. Gr1 CD11b MHCII myeloid cells boost T cell anti-tumor efficacy. Journal of Leukocyte Biology. PMID 29985529 DOI: 10.1002/Jlb.5A0717-276Rr |
0.53 |
|
2018 |
Aqbi HF, Tyutyunyk-Massey L, Keim RC, Butler SE, Thekkudan T, Joshi S, Smith TM, Bandyopadhyay D, Idowu MO, Bear HD, Payne KK, Gewirtz DA, Manjili MH. Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy. Oncotarget. 9: 22113-22122. PMID 29774126 DOI: 10.18632/Oncotarget.25197 |
0.485 |
|
2018 |
Aqbi HF, Wallace M, Sappal S, Payne KK, Manjili MH. IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. Journal of Leukocyte Biology. PMID 29469956 DOI: 10.1002/JLB.5MIR0917-351R |
0.476 |
|
2018 |
Manjili MH. A Theoretical Basis for the Efficacy of Cancer Immunotherapy and Immunogenic Tumor Dormancy: The Adaptation Model of Immunity. Advances in Cancer Research. 137: 17-36. PMID 29405975 DOI: 10.1016/bs.acr.2017.11.005 |
0.389 |
|
2018 |
Meier JA, Fawaz M, Manjili M, Reed JC, Luznik L, Toor AA. Symmetry Analysis of the T Cell Receptor Beta VJ Segment Usage in Allogeneic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.435 |
0.348 |
|
2017 |
Benson Z, Manjili SH, Habibi M, Guruli G, Toor AA, Payne KK, Manjili MH. Conditioning neoadjuvant therapies for improved immunotherapy of cancer. Biochemical Pharmacology. PMID 28803721 DOI: 10.1016/j.bcp.2017.08.007 |
0.365 |
|
2017 |
Lotfi-Emran S, Ward BR, Le QT, Pozez AL, Manjili MH, Woodfolk J, Schwartz LB. Human mast cells present antigen to autologous CD4(+) T Cells. The Journal of Allergy and Clinical Immunology. PMID 28624612 DOI: 10.1016/J.Jaci.2017.02.048 |
0.354 |
|
2017 |
Manjili MH. Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State. Cancer Research. 77: 2564-2569. PMID 28507050 DOI: 10.1158/0008-5472.Can-17-0068 |
0.419 |
|
2016 |
Sulek JE, Robinson SP, Petrossian AA, Zhou S, Goliadze E, Manjili MH, Toor A, Guruli G. Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model. The Prostate. PMID 27862100 DOI: 10.1002/Pros.23275 |
0.424 |
|
2016 |
Manjili MH, Payne KK. Immune Regulatory Function of Tregs. Immunological Investigations. 45: 708-711. PMID 27775448 DOI: 10.1080/08820139.2016.1235394 |
0.383 |
|
2016 |
Zou P, Liu L, Zheng LD, Payne KK, Manjili MH, Idowu MO, Zhang J, Schmelz EM, Cheng Z. Coordinated Upregulation of Mitochondrial Biogenesis and Autophagy in Breast Cancer Cells: The Role of Dynamin Related Protein-1 and Implication for Breast Cancer Treatment. Oxidative Medicine and Cellular Longevity. 2016: 4085727. PMID 27746856 DOI: 10.1155/2016/4085727 |
0.32 |
|
2016 |
Manjili MH, Butler SE. Role of Tregs in Cancer Dormancy or Recurrence. Immunological Investigations. 1-8. PMID 27603507 DOI: 10.1080/08820139.2016.1194428 |
0.533 |
|
2016 |
Terracina KP, Graham LJ, Payne KK, Manjili MH, Baek A, Damle SR, Bear HD. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Cancer Immunology, Immunotherapy : Cii. PMID 27416831 DOI: 10.1007/S00262-016-1868-8 |
0.546 |
|
2016 |
Payne KK, Keim RC, Graham L, Idowu MO, Wan W, Wang XY, Toor AA, Bear HD, Manjili MH. Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells. Journal of Leukocyte Biology. PMID 26928306 DOI: 10.1189/Jlb.5A1215-580R |
0.588 |
|
2016 |
Toor AA, Toor AA, Rahmani M, Manjili MH. On the organization of human T-cell receptor loci: log-periodic distribution of T-cell receptor gene segments. Journal of the Royal Society, Interface / the Royal Society. 13. PMID 26763333 DOI: 10.1098/Rsif.2015.0911 |
0.307 |
|
2015 |
Kravchenko J, Corsini E, Williams MA, Decker W, Manjili MH, Otsuki T, Singh N, Al-Mulla F, Al-Temaimi R, Amedei A, Colacci AM, Vaccari M, Mondello C, Scovassi AI, Raju J, et al. Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. Carcinogenesis. 36: S111-27. PMID 26002081 DOI: 10.1093/Carcin/Bgv033 |
0.433 |
|
2015 |
Toor AA, Sabo RT, Roberts CH, Moore BL, Salman SR, Scalora AF, Aziz MT, Shubar Ali AS, Hall CE, Meier J, Thorn RM, Wang E, Song S, Miller K, Rizzo K, ... ... Manjili MH, et al. Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 1237-45. PMID 25849208 DOI: 10.1016/J.Bbmt.2015.03.011 |
0.357 |
|
2015 |
Toor AA, Sabo R, Salman SR, Moore B, Scalora AF, Aziz M, Kobulnicky J, Meier JA, Shubar Ali AS, Manjili M, Song S, Clark W, McCarty JM, Neale MC, Chung H, et al. Dynamical System Modeling of Immune Reconstitution Following Allogeneic Stem Cell Transplantation (SCT) Conditioned with Rabbit Anti-Thymocyte Globulin Biology of Blood and Marrow Transplantation. 21: S169-S170. DOI: 10.1016/J.Bbmt.2014.11.247 |
0.383 |
|
2014 |
Toor AA, Kobulnicky JD, Salman S, Roberts CH, Jameson-Lee M, Meier J, Scalora A, Sheth N, Koparde V, Serrano M, Buck GA, Clark WB, McCarty JM, Chung HM, Manjili MH, et al. Stem cell transplantation as a dynamical system: are clinical outcomes deterministic? Frontiers in Immunology. 5: 613. PMID 25520720 DOI: 10.3389/Fimmu.2014.00613 |
0.335 |
|
2014 |
Jameson-Lee M, Koparde V, Griffith P, Scalora AF, Sampson JK, Khalid H, Sheth NU, Batalo M, Serrano MG, Roberts CH, Hess ML, Buck GA, Neale MC, Manjili MH, Toor AA. In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation. Frontiers in Immunology. 5: 529. PMID 25414699 DOI: 10.3389/Fimmu.2014.00529 |
0.306 |
|
2014 |
Manjili MH. The inherent premise of immunotherapy for cancer dormancy. Cancer Research. 74: 6745-9. PMID 25411346 DOI: 10.1158/0008-5472.Can-14-2440 |
0.469 |
|
2014 |
Payne KK, Bear HD, Manjili MH. Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. Future Oncology (London, England). 10: 1779-94. PMID 25303057 DOI: 10.2217/Fon.14.97 |
0.52 |
|
2014 |
Manjili MH, Toor AA. Etiology of GVHD: alloreactivity or impaired cellular adaptation? Immunological Investigations. 43: 851-7. PMID 25296238 DOI: 10.3109/08820139.2014.953636 |
0.449 |
|
2014 |
Manjili MH, Wang XY, Abrams S. Evolution of Our Understanding of Myeloid Regulatory Cells: From MDSCs to Mregs. Frontiers in Immunology. 5: 303. PMID 25071764 DOI: 10.3389/Fimmu.2014.00303 |
0.451 |
|
2014 |
Manjili MH. The adaptation model of immunity. Immunotherapy. 6: 59-70. PMID 24341885 DOI: 10.2217/imt.13.157 |
0.303 |
|
2014 |
Bot A, Chiriva-Internati M, Cornforth A, Czerniecki BJ, Ferrone S, Geles K, Greenberg PD, Hurt E, Koya RC, Manjili MH, Matsui W, Morgan RA, Palena CM, Powell Jr DJ, Restifo NP, et al. Stem cells and cancer immunotherapy: Arrowhead’s 2nd annual cancer immunotherapy conference Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-6 |
0.348 |
|
2014 |
Jameson-Lee M, Koparde VN, Sampson JK, Scalora AF, Khalid H, Sheth N, Griffith P, Serrano MG, Lee V, Roberts CH, Neale MC, Buck GA, Manjili M, Toor AA. In Silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem Cell Transplant Donor-Recipient Pairs Biology of Blood and Marrow Transplantation. 20: S269-S270. DOI: 10.1016/J.Bbmt.2013.12.454 |
0.306 |
|
2013 |
Gowda M, Payne KK, Godder K, Manjili MH. HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma. Oncoimmunology. 2: e26616. PMID 24349875 DOI: 10.4161/Onci.26616 |
0.459 |
|
2013 |
Kmieciak M, Payne KK, Wang XY, Manjili MH. IFN-γ Rα is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse. Plos One. 8: e82544. PMID 24324806 DOI: 10.1371/Journal.Pone.0082544 |
0.552 |
|
2013 |
Payne KK, Zoon CK, Wan W, Marlar K, Keim RC, Kenari MN, Kazim AL, Bear HD, Manjili MH. Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells. Breast Cancer Research and Treatment. 142: 45-57. PMID 24197563 DOI: 10.1007/S10549-013-2733-5 |
0.592 |
|
2013 |
Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines: past, present, and future. Advances in Cancer Research. 119: 421-75. PMID 23870514 DOI: 10.1016/B978-0-12-407190-2.00007-1 |
0.336 |
|
2013 |
El Shikh ME, Kmieciak M, Manjili MH, Szakal AK, Pitzalis C, Tew JG. Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells. Human Vaccines & Immunotherapeutics. 9: 2434-44. PMID 23836278 DOI: 10.4161/Hv.25596 |
0.353 |
|
2013 |
Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, ... Manjili MH, et al. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. Journal of Translational Medicine. 11: 145. PMID 23758773 DOI: 10.1186/1479-5876-11-145 |
0.451 |
|
2013 |
Meier J, Roberts C, Avent K, Hazlett A, Berrie J, Payne K, Hamm D, Desmarais C, Sanders C, Hogan KT, Archer KJ, Manjili MH, Toor AA. Fractal organization of the human T cell repertoire in health and after stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 366-77. PMID 23313705 DOI: 10.1016/J.Bbmt.2012.12.004 |
0.386 |
|
2013 |
Payne KK, Zoon CK, Wan W, Marlar K, Keim RC, Kenari MN, Kazim L, Bear HD, Manjili MH. Peripheral blood mononuclear cells of breast cancer patients can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P170 |
0.51 |
|
2013 |
Thorn R, Meier J, Wang E, Sabo RT, Scalora AF, Roberts CH, Song S, Manjili MH, Clark WB, McCarty JM, Chung HM, Toor AA. Favorable T Cell Reconstitution In Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation with Low-Dose Rabbit Anti-Thymocyte Globulin and Total Body Irradiation Blood. 122: 4577-4577. DOI: 10.1182/Blood.V122.21.4577.4577 |
0.348 |
|
2013 |
El Shikh M, Biggioggero M, El Sayed R, Kmieciak M, Manjili M, Szakal A, Meroni P, Pitzalis C, Tew J. OP0218 Regulation of auto-antibody production by auto-immune complexes on follicular dendritic cells Annals of the Rheumatic Diseases. 71: 129.3-129. DOI: 10.1136/Annrheumdis-2012-Eular.1901 |
0.416 |
|
2012 |
Manjili MH, Egilmez N, Knutson KL, Selvan SR, Ostberg JR. Tumor escape and progression under immune pressure. Clinical & Developmental Immunology. 2012: 641079. PMID 23316254 DOI: 10.1155/2012/641079 |
0.578 |
|
2012 |
Payne KK, Toor AA, Wang XY, Manjili MH. Immunotherapy of cancer: reprogramming tumor-immune crosstalk. Clinical & Developmental Immunology. 2012: 760965. PMID 23097673 DOI: 10.1155/2012/760965 |
0.579 |
|
2012 |
Manjili MH. Phenotypic plasticity of MDSC in cancers. Immunological Investigations. 41: 711-21. PMID 23017142 DOI: 10.3109/08820139.2012.673670 |
0.529 |
|
2012 |
Payne KK, Manjili MH. Adaptive immune responses associated with breast cancer relapse. Archivum Immunologiae Et Therapiae Experimentalis. 60: 345-50. PMID 22911133 DOI: 10.1007/S00005-012-0185-Y |
0.602 |
|
2012 |
Toor AA, Payne KK, Chung HM, Sabo RT, Hazlett AF, Kmieciak M, Sanford K, Williams DC, Clark WB, Roberts CH, McCarty JM, Manjili MH. Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity. British Journal of Haematology. 158: 700-11. PMID 22816680 DOI: 10.1111/J.1365-2141.2012.09225.X |
0.455 |
|
2012 |
Manjili MH, Payne KK. Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems. Oncoimmunology. 1: 201-204. PMID 22720242 DOI: 10.4161/Onci.1.2.18113 |
0.443 |
|
2012 |
Saleem SJ, Martin RK, Morales JK, Sturgill JL, Gibb DR, Graham L, Bear HD, Manjili MH, Ryan JJ, Conrad DH. Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity. Journal of Immunology (Baltimore, Md. : 1950). 189: 511-5. PMID 22706087 DOI: 10.4049/Jimmunol.1200647 |
0.766 |
|
2012 |
Berrie JL, Kmieciak M, Sabo RT, Roberts CH, Idowu MO, Mallory K, Chung HM, McCarty JM, Borrelli CA, Detwiler MM, Kazim AL, Toor AA, Manjili MH. Distinct oligoclonal T cells are associated with graft versus host disease after stem-cell transplantation. Transplantation. 93: 949-57. PMID 22377792 DOI: 10.1097/Tp.0B013E3182497561 |
0.475 |
|
2012 |
Yi H, Zuo D, Yu X, Hu F, Manjili MH, Chen Z, Subjeck JR, Wang XY. Suppression of antigen-specific CD4+ T cell activation by SRA/CD204 through reducing the immunostimulatory capability of antigen-presenting cell. Journal of Molecular Medicine (Berlin, Germany). 90: 413-26. PMID 22083206 DOI: 10.1007/S00109-011-0828-1 |
0.409 |
|
2012 |
Toor AA, Sabo RT, Chung HM, Roberts C, Manjili RH, Song S, Williams DC, Edmiston W, Gatesman ML, Edwards RW, Ferreira-Gonzalez A, Clark WB, Neale MC, McCarty JM, Manjili MH. Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 18: 794-804. PMID 22005648 DOI: 10.1016/J.Bbmt.2011.10.011 |
0.406 |
|
2012 |
Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Human Pathology. 43: 364-73. PMID 21835433 DOI: 10.1016/J.Humpath.2011.05.005 |
0.433 |
|
2012 |
Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, Bear HD, Marincola FM, Manjili MH. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Research and Treatment. 131: 871-80. PMID 21479927 DOI: 10.1007/S10549-011-1470-X |
0.495 |
|
2012 |
Ascierto ML, Idowu MO, Zhao Y, Bedognetti D, Ascierto PA, Bear HD, Wang E, Marincola F, Maria AD, Manjili M. Involvement of NK cell molecular signatures in favorable prognosis of breast cancer patients. Journal of Clinical Oncology. 30: 10565-10565. DOI: 10.1200/Jco.2012.30.15_Suppl.10565 |
0.476 |
|
2012 |
Meier J, Hazlett AF, Avent K, Berrie J, Payne K, Hamm D, Desmarais C, Sanders C, Hogan KT, Grant S, Archer KJ, Manjili MH, Roberts C, Toor AA. Fractal Organization of the Human T Cell Repertoire in Health and Following Stem Cell Transplantation Blood. 120: 4193-4193. DOI: 10.1182/Blood.V120.21.4193.4193 |
0.348 |
|
2012 |
El Shikh MEM, Biggioggero M, El Sayed RM, Kmieciak M, Manjili MH, Szakal AK, Meroni PL, Pitzalis C, Tew JG. Regulation of auto-antibody production by persisting auto-immune complexes on follicular dendritic cells Annals of the Rheumatic Diseases. 71: A38.1-A38. DOI: 10.1136/Annrheumdis-2011-201234.15 |
0.413 |
|
2011 |
Ascierto ML, Kmieciak M, Idowu MO, Bedognetti D, De Maria A, Bear HD, Wang E, Marincola F, Manjili M. Immunologic markers associated with favorable prognosis in breast cancer patients: Role of innate immune system. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 43. PMID 27957969 DOI: 10.1200/Jco.2011.29.27_Suppl.43 |
0.477 |
|
2011 |
Gowda M, Godder K, Kmieciak M, Worschech A, Ascierto ML, Wang E, Marincola FM, Manjili MH. Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. Journal of Translational Medicine. 9: 170. PMID 21978632 DOI: 10.1186/1479-5876-9-170 |
0.438 |
|
2011 |
Yi H, Guo C, Yu X, Gao P, Qian J, Zuo D, Manjili MH, Fisher PB, Subjeck JR, Wang XY. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity. Cancer Research. 71: 6611-20. PMID 21914786 DOI: 10.1158/0008-5472.Can-11-1801 |
0.407 |
|
2011 |
Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Spivey TL, Murtas D, Uccellini L, Ayotte BD, Stroncek DF, Chouchane L, Manjili MH, Wang E, Marincola FM. An immunologic portrait of cancer. Journal of Translational Medicine. 9: 146. PMID 21875439 DOI: 10.1186/1479-5876-9-146 |
0.406 |
|
2011 |
Zhang Q, Sturgill JL, Kmieciak M, Szczepanek K, Derecka M, Koebel C, Graham LJ, Dai Y, Chen S, Grant S, Cichy J, Shimoda K, Gamero A, Manjili M, Bear H, et al. The role of Tyk2 in regulation of breast cancer growth. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 31: 671-7. PMID 21864028 DOI: 10.1089/Jir.2011.0023 |
0.497 |
|
2011 |
Kmieciak M, Basu D, Payne KK, Toor A, Yacoub A, Wang XY, Smith L, Bear HD, Manjili MH. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. Journal of Immunology (Baltimore, Md. : 1950). 187: 708-17. PMID 21670315 DOI: 10.4049/Jimmunol.1100502 |
0.562 |
|
2011 |
Manjili MH, Toor A. Comment on "Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses". Journal of Immunology (Baltimore, Md. : 1950). 186: 6071; author reply 6. PMID 21597038 DOI: 10.4049/Jimmunol.1190017 |
0.433 |
|
2011 |
Manjili MH. Revisiting cancer immunoediting by understanding cancer immune complexity. The Journal of Pathology. 224: 5-9. PMID 21480229 DOI: 10.1002/Path.2865 |
0.383 |
|
2011 |
Kmieciak M, Payne KK, Idowu MO, Grimes MM, Graham L, Ascierto ML, Wang E, Wang XY, Bear HD, Manjili MH. Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. Journal of Translational Medicine. 9: 35. PMID 21453513 DOI: 10.1186/1479-5876-9-35 |
0.503 |
|
2011 |
Kmieciak M, Toor A, Graham L, Bear HD, Manjili MH. Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation. Journal of Visualized Experiments : Jove. PMID 21304453 DOI: 10.3791/2381 |
0.539 |
|
2011 |
Yi H, Yu X, Guo C, Manjili MH, Repasky EA, Wang XY. Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens. Cancer Immunology, Immunotherapy : Cii. 60: 349-60. PMID 21088965 DOI: 10.1007/S00262-010-0939-5 |
0.433 |
|
2011 |
Kmieciak M, Worschech A, Nikizad H, Gowda M, Habibi M, Depcrynski A, Wang E, Godder K, Holt SE, Marincola FM, Manjili MH. CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. Breast Cancer Research and Treatment. 126: 385-94. PMID 20480224 DOI: 10.1007/S10549-010-0942-8 |
0.471 |
|
2011 |
Toor AA, Sabo RT, Chung HM, Roberts CH, Manjili RH, Song S, Williams DC, Clark W, Manjili MH, McCarty JM. Favorable Outcomes in Patients with High Donor-Derived T Cell Count Following In Vivo T Cell Depleted Reduced Intensity Allogeneic Stem Cell Transplantation Blood. 118: 3043-3043. DOI: 10.1182/Blood.V118.21.3043.3043 |
0.378 |
|
2011 |
Toor AA, Payne K, Chung HM, Roberts CH, Sabo RT, Kmieciak M, Clark W, McLaughlin C, Buskey A, Anderson J, Manjili RH, Roseff SD, McCarty JM, Manjili MH. Adaptive Immunotherapy In Multiple Myeloma: Epigenetic Modification and Immunomodulation by Sequential Azacitidine and Lenalidomide to Generate Cancer Testis Antigen Specific Cellular Immune Response Blood. 118: 2926-2926. DOI: 10.1182/Blood.V118.21.2926.2926 |
0.404 |
|
2011 |
Payne KK, Kmieciak M, Basu D, Ramakrishnan V, Bear HD, Manjili MH. Abstract 775: Sequential common gamma-chain cytokines facilitate differentiation of tumor-reactive T cells that are resistant to MDSC and can induce rejection of breast tumors Immunology. 71: 775-775. DOI: 10.1158/1538-7445.Am2011-775 |
0.513 |
|
2011 |
El Shikh ME, El Sayed RM, Kmieciak M, Manjili M, Szakal A, Pitzalis C, Tew J. Breakage of B cell tolerance by antigens on follicular dendritic cells Annals of the Rheumatic Diseases. 70: A57-A57. DOI: 10.1136/Ard.2010.148999.9 |
0.391 |
|
2011 |
Toor A, Kmieciak M, Berrie J, Mallory K, Roberts C, Sabo R, Idowu M, Chung H, Veronica B, Clark W, McCarty J, Detwiler M, Kazim L, Manjili M. Distinct Oligoclonal T Cells Are Associated With GVHD or GVHD-Free Responses in Patients With Hematologic Malignancies Following Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 17: S329-S330. DOI: 10.1016/J.Bbmt.2010.12.528 |
0.414 |
|
2010 |
Arnouk H, Zynda ER, Wang XY, Hylander BL, Manjili MH, Repasky EA, Subjeck JR, Latif Kazim A. Tumour secreted grp170 chaperones full-length protein substrates and induces an adaptive anti-tumour immune response in vivo. International Journal of Hyperthermia : the Official Journal of European Society For Hyperthermic Oncology, North American Hyperthermia Group. 26: 366-75. PMID 20210603 DOI: 10.3109/02656730903485910 |
0.395 |
|
2010 |
Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells Breast Cancer Research and Treatment. 123: 39-49. PMID 19898981 DOI: 10.1007/S10549-009-0622-8 |
0.793 |
|
2010 |
Cha E, Graham L, Manjili MH, Bear HD. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Research and Treatment. 122: 359-69. PMID 19826947 DOI: 10.1007/s10549-009-0573-0 |
0.374 |
|
2010 |
Ochiai K, Singh H, Vu T, Funnell A, Gatto D, Brink R, Pearson R, Crossley M, Minamino K, Adachi T, Nagaoka K, Takahara K, Taki S, Inaba K, Touma M, ... ... Manjili M, et al. B cell development (WS-030) Chairpersons: Daisuke Kitamura, David Gray International Immunology. 22. DOI: 10.1093/Intimm/Dxq187 |
0.3 |
|
2009 |
Kmieciak M, Gowda M, Graham L, Godder K, Bear HD, Marincola FM, Manjili MH. Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. Journal of Translational Medicine. 7: 89. PMID 19849846 DOI: 10.1186/1479-5876-7-89 |
0.35 |
|
2009 |
Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. International Immunopharmacology. 9: 900-9. PMID 19336265 DOI: 10.1016/j.intimp.2009.03.015 |
0.779 |
|
2009 |
Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Research. 69: 2887-95. PMID 19276366 DOI: 10.1158/0008-5472.Can-08-3343 |
0.519 |
|
2009 |
Le HK, Graham L, Miller CH, Kmieciak M, Manjili MH, Bear HD. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunology, Immunotherapy : Cii. 58: 1565-76. PMID 19198835 DOI: 10.1007/s00262-009-0666-y |
0.319 |
|
2009 |
Morales JK, Kmieciak M, Graham L, Feldmesser M, Bear HD, Manjili MH. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunology, Immunotherapy : Cii. 58: 941-53. PMID 18979098 DOI: 10.1007/S00262-008-0609-Z |
0.791 |
|
2009 |
Habibi M, Kmieciak M, Graham L, Morales JK, Bear HD, Manjili MH. Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis. Breast Cancer Research and Treatment. 114: 423-31. PMID 18425677 DOI: 10.1007/S10549-008-0024-3 |
0.778 |
|
2009 |
Manjili M, Roberts CH, Kmieciak M, Gowda MS, Ferreira-Gonzalez A, Archer K, Song S, Chung HM, McCarty JM, Toor A. Oligoclonal T Cells Associated with Gvhd Following Allogeneic Stem Cell Transplantation Conditioned with Thymoglobulin and Reduced Intensity Total Body Irradiation. Blood. 114: 4662-4662. DOI: 10.1182/Blood.V114.22.4662.4662 |
0.37 |
|
2008 |
Ghadersohi A, Odunsi K, Zhang S, Azrak RG, Bundy BN, Manjili MH, Li F. Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients International Journal of Cancer. 123: 1376-1384. PMID 18567002 DOI: 10.1002/Ijc.23667 |
0.412 |
|
2008 |
Manjili MH, Kmieciak M. Does HER-2/neu antigen loss in metastatic breast tumors occur under immune pressure? International Journal of Cancer. 123: 1476-7; author reply. PMID 18566999 DOI: 10.1002/Ijc.23663 |
0.482 |
|
2008 |
Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, Marincola FM, Manjili MH. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Research. 68: 2436-46. PMID 18381452 DOI: 10.1158/0008-5472.Can-07-6822 |
0.59 |
|
2008 |
Kmieciak M, Morales JK, Morales J, Bolesta E, Grimes M, Manjili MH. Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design. Cancer Immunology, Immunotherapy : Cii. 57: 1391-8. PMID 18278493 DOI: 10.1007/S00262-008-0475-8 |
0.779 |
|
2007 |
Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression Seminars in Cancer Biology. 17: 275-287. PMID 17662614 DOI: 10.1016/J.Semcancer.2007.06.009 |
0.549 |
|
2007 |
Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses European Journal of Immunology. 37: 675-685. PMID 17304628 DOI: 10.1002/Eji.200636639 |
0.587 |
|
2006 |
Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR, Kazim AL. Erratum to: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Research and Treatment. 96: 243. PMID 28303485 DOI: 10.1007/S10549-006-9163-6 |
0.487 |
|
2006 |
Segal BH, Wang XY, Dennis CG, Youn R, Repasky EA, Manjili MH, Subjeck JR. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discovery Today. 11: 534-40. PMID 16713905 DOI: 10.1016/J.Drudis.2006.04.016 |
0.437 |
|
2006 |
Manjili MH, Kmieciak M, Keeler J. Comment on "Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma". Journal of Immunology (Baltimore, Md. : 1950). 176: 4511; author reply 4. PMID 16585536 |
0.411 |
|
2006 |
Manjili MH, Park JE, Facciponte JG, Wang XY, Subjeck JR. Immunoadjuvant chaperone, GRP170, induces 'danger signals' upon interaction with dendritic cells. Immunology and Cell Biology. 84: 203-8. PMID 16519738 DOI: 10.1111/J.1440-1711.2006.01418.X |
0.357 |
|
2006 |
Park JE, Facciponte J, Chen X, MacDonald I, Repasky EA, Manjili MH, Wang XY, Subjeck JR. Chaperoning function of stress protein grp170, a member of the hsp70 superfamily, is responsible for its immunoadjuvant activity. Cancer Research. 66: 1161-8. PMID 16424054 DOI: 10.1158/0008-5472.Can-05-2609 |
0.354 |
|
2006 |
Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR, Kazim AL. Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Research and Treatment. 96: 233-41. PMID 16211331 DOI: 10.1007/S10549-005-9044-4 |
0.561 |
|
2006 |
Facciponte JG, Wang XY, MacDonald IJ, Park JE, Arnouk H, Grimm MJ, Li Y, Kim H, Manjili MH, Easton DP, Subjeck JR. Heat shock proteins HSP70 and GP96: structural insights. Cancer Immunology, Immunotherapy : Cii. 55: 339-46. PMID 16032399 DOI: 10.1007/S00262-005-0020-Y |
0.488 |
|
2005 |
Manjili MH, Park J, Facciponte JG, Subjeck JR. HSP110 induces "danger signals" upon interaction with antigen presenting cells and mouse mammary carcinoma. Immunobiology. 210: 295-303. PMID 16164037 DOI: 10.1016/J.Imbio.2005.04.002 |
0.403 |
|
2005 |
Facciponte JG, MacDonald IJ, Wang XY, Kim H, Manjili MH, Subjeck JR. Heat shock proteins and scavenger receptors: role in adaptive immune responses. Immunological Investigations. 34: 325-42. PMID 16136784 DOI: 10.1081/Imm-200064505 |
0.462 |
|
2005 |
Manjili M, Kmieciak M. Characterization of Primary and Immune Escape Variant of HER-2/neu Overexpressing Mouse Mammary Carcinoma Journal of Immunotherapy. 28: 646. DOI: 10.1097/01.Cji.0000191056.58264.74 |
0.393 |
|
2003 |
Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 171: 4054-61. PMID 14530326 DOI: 10.4049/Jimmunol.171.8.4054 |
0.536 |
|
2002 |
Wang XY, Li Y, Manjili MH, Repasky EA, Pardoll DM, Subjeck JR. Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor. Cancer Immunology, Immunotherapy : Cii. 51: 311-9. PMID 12111119 DOI: 10.1007/S00262-002-0287-1 |
0.399 |
|
Show low-probability matches. |